References: 1. Guardant360® Liquid CDx Assay Specifications. April 2026. Guardant Health, Inc. Redwood City, CA. 2. Riely GJ, Wood DE, Ettinger DS, et al. NCCN Guidelines®® Insights: Non-Small Cell Lung Cancer, Version 5.2024. NCCN clinical practice guidelines in oncology. Accessed June 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf 3. Gradishar WJ, Moran MS, Abraham J, et al. NCCN Guidelines® Insights: Breast Cancer, Version 2.2024. NCCN clinical practice guidelines in oncology. Accessed June 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf 4. Benson AB, Venook AP, Almahdi M, et al. NCCN Guidelines® Insights: Colon Cancer, Version 3.2024. NCCN clinical practice guidelines in oncology. Accessed June 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf 5. Schaeffer EM, Srinivas S, Adra N, et al. NCCN Guidelines® Insights: Prostate Cancer, Version 4.2024. NCCN clinical practice guidelines in oncology. Accessed June 1, 2024. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
Home Screening MRD + Monitoring Treatment Selection
Multiple FDA-approved companion diagnostics approvals across NSCLC, breast cancer, and colorectal cancer1-5
| Indication | Biomarker | Therapy |
|---|---|---|
| Breast cancer |
ESR1 missense mutations between codons 310 and 547 |
ORSERDU® (elacestrant) |
|
ESR1 E380, V422del, S463, L469, L536, Y537, and D538 mutations |
INLURIYO™ (imlunestrant) |
|
|
Colorectal cancer |
BRAF V600E |
BRAFTOVI® (encorafenib) in combination with ERBITUX® (cetuximab) |
|
Non-small cell lung cancer |
EGFR exon 19 deletions, L858R, and T790M* |
TAGRISSO® (osimertinib) |
| EGFR exon 20 insertions |
RYBREVANT® (amivantamab-vmjw) |
|
| KRAS G12C |
LUMAKRAS™ (sotorasib) |
|
|
ERBB2/HER2 activating mutations (SNVs and exon 20 insertions) |
ENHERTU® (fam-trastuzumab deruxtecan-nxki) |